Business
Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series
SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene
About this update from Clene Inc.
[{"type":"text","content":"SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will participate in Roth’s 35th Annual Healthcare Conference set for March 12th-14th and in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on March 7th and 22nd. EVENT DETAILS: Roth 35th Annual Healthcare Conference, March 12-14 Presentation/Fireside Chat Time: March 13 starting at 3:30 p.m. E.D.TWebcast link: https://wsw.com/webcast/roth46/clnn/1826765 The webcast of this presentation will be posted to the Investors section of the Company’s website located at www.invest.clene.com. Renmark Virtual Non-Deal Roadshow Series Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will deliver the latest investor presentation followed by a live Q&A session. Individuals can register by using the link below. March 7 – 4 p.m. EDT, https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-03-07-130000 March 22 – 2 p.m. EDT, https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-03-22-130000 Registration for the Renmark events may be limited but access to the replays will be posted to the Investors section of the Company’s website within a few days of the events. To ensure smooth connectivity, please access this link using the latest version of Google Chrome. About Clene Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook. Contacts: Renmark Financial Communications Inc.James R. Kautz: [email protected].: (416) 644-2020 or (212) 812-7680www.renmarkfinancial.com Media Contact Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, [email protected]@russopartnersllc.com(858) 717-2310 Investor ContactKevin GardnerLifeSc...